Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: A case report of late response after pseudoprogression

Patrick Grierson; Danielle Crites; Marianna B. Ruzinova; Motoyo Yano; Kian Huat Lim

doi:10.1002/hep4.1132

Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: A case report of late response after pseudoprogression

Patrick Grierson, Danielle Crites, Marianna B. Ruzinova, Motoyo Yano, Kian Huat Lim

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

There are few effective therapies for unresectable or metastatic hepatocellular carcinoma. Recent data have demonstrated efficacy of immune checkpoint blockade in this difficult to treat disease; however, clinical experience is limited. We report a case of hepatocellular carcinoma displaying pseudoprogression followed by a late response with novel magnetic resonance imaging features following treatment with the anti-programmed cell death protein 1 agent pembrolizumab. (Hepatology Communications 2018;2:148–151).

Original language	English
Pages (from-to)	148-151
Number of pages	4
Journal	Hepatology Communications
Volume	2
Issue number	2
DOIs	https://doi.org/10.1002/hep4.1132
State	Published - 2018

Access to Document

10.1002/hep4.1132

Cite this

@article{ee5c6005418b425f8444481f9ee91cda,

title = "Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: A case report of late response after pseudoprogression",

abstract = "There are few effective therapies for unresectable or metastatic hepatocellular carcinoma. Recent data have demonstrated efficacy of immune checkpoint blockade in this difficult to treat disease; however, clinical experience is limited. We report a case of hepatocellular carcinoma displaying pseudoprogression followed by a late response with novel magnetic resonance imaging features following treatment with the anti-programmed cell death protein 1 agent pembrolizumab. (Hepatology Communications 2018;2:148–151).",

author = "Patrick Grierson and Danielle Crites and Ruzinova, {Marianna B.} and Motoyo Yano and Lim, {Kian Huat}",

note = "Publisher Copyright: {\textcopyright} 2017 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.",

year = "2018",

doi = "10.1002/hep4.1132",

language = "English",

volume = "2",

pages = "148--151",

journal = "Hepatology Communications",

issn = "2471-254X",

number = "2",

}

Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: A case report of late response after pseudoprogression. / Grierson, Patrick; Crites, Danielle; Ruzinova, Marianna B. et al.
In: Hepatology Communications, Vol. 2, No. 2, 2018, p. 148-151.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab

T2 - A case report of late response after pseudoprogression

AU - Grierson, Patrick

AU - Crites, Danielle

AU - Ruzinova, Marianna B.

AU - Yano, Motoyo

AU - Lim, Kian Huat

PY - 2018

Y1 - 2018

N2 - There are few effective therapies for unresectable or metastatic hepatocellular carcinoma. Recent data have demonstrated efficacy of immune checkpoint blockade in this difficult to treat disease; however, clinical experience is limited. We report a case of hepatocellular carcinoma displaying pseudoprogression followed by a late response with novel magnetic resonance imaging features following treatment with the anti-programmed cell death protein 1 agent pembrolizumab. (Hepatology Communications 2018;2:148–151).

AB - There are few effective therapies for unresectable or metastatic hepatocellular carcinoma. Recent data have demonstrated efficacy of immune checkpoint blockade in this difficult to treat disease; however, clinical experience is limited. We report a case of hepatocellular carcinoma displaying pseudoprogression followed by a late response with novel magnetic resonance imaging features following treatment with the anti-programmed cell death protein 1 agent pembrolizumab. (Hepatology Communications 2018;2:148–151).

UR - http://www.scopus.com/inward/record.url?scp=85087410172&partnerID=8YFLogxK

U2 - 10.1002/hep4.1132

DO - 10.1002/hep4.1132

M3 - Article

AN - SCOPUS:85087410172

SN - 2471-254X

VL - 2

SP - 148

EP - 151

JO - Hepatology Communications

JF - Hepatology Communications

IS - 2

ER -

Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: A case report of late response after pseudoprogression

Abstract

Access to Document

Other files and links

Fingerprint

Cite this